PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors

Author(s): Julia Alejandra Pezuk, Elvis Terci Valera, María Sol Brassesco

Journal Name: Current Drug Targets

Volume 17 , Issue 14 , 2016

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Graphical Abstract:


Over the years, polo-like kinase 1 (PLK1) has garnered great interest as a therapeutic target. The PLK1 is a member of a highly conserved serine/threonine kinase family that plays pivotal roles in mitosis, cytokinesis and DNA damage response in eukaryotic cells. In this review, we summarize the functions of PLK1 during cell cycle progression, its roles in human pediatric cancer and its value as a prognostic factor. Furthermore, we introduce the advances in pharmacological inhibition and the newly chemotherapeutic development of small-molecules to target PLK1 in cancer treatment. Finally, clinical trials with PLK1 inhibitors are briefly reviewed.

Keywords: Chemotherapy, inhibitors, pediatric tumors, PLK1, radiotherapy, treatment.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 29 September, 2016
Page: [1661 - 1672]
Pages: 12
DOI: 10.2174/1389450116666150825120235
Price: $65

Article Metrics

PDF: 32
PRC: 2